2010 Chinese guidelines for the management of hypertension

The 2010 Chinese guidelines for the management of hypertension is an update of the previous versions in 2005 and 1999. A guideline committee of nearly 100 members appointed by the Chinese Hypertension League (CHL) and the National Centre for Cardiovascular Disease (NCCD), in collaboration with the Chinese societies of cardiology, nephrology, neurology, gynecology and endocrinology, convened on several occasions and discussed the guidelines, drafted by a core writing group. The prevalence of hypertension has been increasing in China for decades, and reached 18.8% in the year 2002. The rates of awareness, treatment and control for hypertension patients remain low compared to high income countries, in spite of substantial improvements since 1991. In some communities, the control rate of hypertension increased up to 60%. The mortality rate of stroke, which is the major complication of hypertension in the Chinese population, gradually decreased during the period, more so in urban areas than in rural areas for the middle-aged and elderly populations; in the younger age groups, however, it increased. As hypertension is a "cardiovascular syndrome", the management strategy should be based on the overall risk of cardiovascular disease estimated with all related risk factors, target organ damage and co-morbidity of patients. The target blood pressure is set at SBP/DBP <140/90 mm Hg(1 mm Hg=0.133 kPa) in uncomplicated hypertension; <150/90 mm Hg for the elderly (≥65 years) or, if tolerable, <140/90 mm Hg; and <130/80 mm Hg for those with diabetes, coronary heart disease or renal disease. For these high risk patients, the management should be individualised. In general, lifestyle modification, such as sodium restriction, smoking cessation, moderation of body weight and alcohol consumption, and increasing dietary potassium intake and physical activity, should be implemented for prevention and control of hypertension. Five classes of antihypertensive drugs, including calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin type Ⅱ receptor blockers, diuretics and β-blockers, as well as single pill combinations of these agents, can be used for initial and maintenance of antihypertensive treatment. Several populations require special attention in the prevention and control of hypertension, such as children and adolescents, the elderly, pregnant women, and patients with various cardiovascular complications. Since health-care policies and resources vary substantially from one place to another, two levels of recommendations of management are proposed: a sophisticated and a basic, allowing doctors-in-charge to manage their patients in a more feasible way.
序言 高血压是最常见的慢性病,也是心脑血管病最主要的危险因素,其脑卒中、心肌梗死、心力衰竭及慢性肾脏病等主要并发症,不仅致残、致死率高,而且严重消耗医疗和社会资源,给家庭和国家造成沉重负担.国内外的实践证明,高血压是可以预防和控制的疾病,降低高血压患者的血压水平,可明显减少脑卒中及心脏病事件,显著改善患者的生存质量,有效降低疾病负担.
Author: 中国高血压防治指南修订委员会
Author(En): Writing Group of 2010 Chinese Guidelines for the Management of Hypertension
Author's Affiliation:
Volume, Issue, Pages: 2011, 39(7) ,579-616
ISSN: 0253-3758
Classification: R544.1
Keywords:Hypertension  Drug therapy  Disease management  Guidelines  
Computer Assigned CLC Code: R18 R54
Supporting Funds:
返回顶部Cited Literatures
返回顶部Related Papers
返回顶部Related Blogs